Savara's MOLBREEVI U.K. Approval Path Accelerated
Event summary
- Savara’s MOLBREEVI marketing authorization application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) has been accepted by the U.K.’s MHRA.
- The MHRA’s acceptance is under Accelerated Review, with a 150-day assessment duration, leading to a decision expected in Q4 2026.
- MOLBREEVI is also under Priority Review by the FDA (PDUFA date: August 22, 2026) and review by the CHMP (decision expected in Q1 2027).
- MOLBREEVI has received Orphan Drug Designation from both the FDA and EMA, and Innovation Passport and Promising Innovative Medicine designations from the MHRA.
The big picture
Savara's progress with MOLBREEVI represents a significant opportunity in the underserved rare disease space, particularly given the limited treatment options for Autoimmune PAP. The accelerated review by the MHRA suggests a favorable assessment of the drug's potential, but the concurrent reviews by the FDA and CHMP create a complex timeline with multiple potential inflection points. The company's ability to navigate these regulatory hurdles and establish a commercial presence will be critical to its long-term success.
What we're watching
- Regulatory Risk
- While the accelerated review is positive, the 150-day timeline is aggressive and hinges on MHRA’s assessment of clinical data; any unexpected requests for additional information could delay the decision.
- Commercialization
- The success of MOLBREEVI in the U.K. market will depend on Savara’s ability to establish a distribution network and effectively reach a small, geographically dispersed patient population.
- Competitive Landscape
- The approval of MOLBREEVI will likely intensify scrutiny of other therapies targeting Autoimmune PAP, potentially accelerating development and commercialization efforts by competitors.
Related topics